We're excited to announce a major milestone in our mission to revolutionize regenerative medicine. Our innovative biomanufacturing technology, using our Small Mobile Stem (SMS) Cells, has been recognized with the issuance of U.S. Patent No. 12,146,164.
SMS cells offer a potentially superior alternative to other cell therapies on the market. They possess unique properties that make them a highly accessible technology with no logistical challenges. The cells prove to be effective in treating a wide range of severe conditions and unmet needs.
A Strong Foundation for the Future
This patent significantly promotes the establishment of a state-of-the-art bio-manufacturing facility, enabling us to produce large-scale, high-quality SMS cells for treating widespread indications.
We invite you to follow our journey and become part of the SMSbiotech community. Together, we intend to unlock the full potential of stem cell therapy and improve the lives of countless patients.